5 Stocks With Recent Price Strength Amid October Volatility

Core Viewpoint - October has historically been a volatile month for Wall Street, and this year is no exception, with volatility driven by various factors including better-than-expected jobs data, expectations of a gradual Fed rate cut, rising Treasury yields, geopolitical tensions, and the upcoming U.S. Presidential election [1] Group 1: Market Conditions - U.S. stock markets have experienced significant volatility since the beginning of October [1] - Factors contributing to this volatility include strong jobs data for September and expectations of a gradual rather than aggressive Fed rate cut [1] - The yield on the benchmark 10-Year Treasury Note has increased, adding to market uncertainty [1] - Geopolitical conflicts in the Middle East and the upcoming U.S. Presidential election are also influencing market dynamics [1] Group 2: Stock Performance - A selection of stocks has shown price strength amidst the volatility, particularly those on a recent bull run [1] - Five highlighted stocks include Atour Lifestyle Holdings Ltd. (ATAT), Vertiv Holdings Co. (VRT), Corcept Therapeutics Inc. (CORT), Qifu Technology Inc. (QFIN), and ADMA Biologics Inc. (ADMA) [1] Group 3: Stock Analysis - Atour Lifestyle Holdings Ltd. (ATAT): Stock price increased by 39% in the past four weeks, with expected earnings growth of 32.6% for the current year and a 10.9% improvement in the Zacks Consensus Estimate over the last 60 days [4] - Vertiv Holdings Co. (VRT): Stock price rose by 31.2% in the past four weeks, with an expected earnings growth rate of 45.8% for the current year and a 6.2% improvement in the Zacks Consensus Estimate over the last 90 days [5] - Corcept Therapeutics Inc. (CORT): Stock price surged by 29.2% in the past four weeks, with an expected earnings growth rate of 19.2% for the current year and a 1.8% improvement in the Zacks Consensus Estimate over the last 30 days [6] - Qifu Technology Inc. (QFIN): Stock price appreciated by 25% in the past four weeks, with expected earnings growth of 38% for the current year and a 2.8% improvement in the Zacks Consensus Estimate over the last 30 days [7] - ADMA Biologics Inc. (ADMA): Stock price advanced by 20.2% in the past four weeks, with an expected earnings growth rate of 29.6% for next year and an 8.5% improvement in the Zacks Consensus Estimate over the last 60 days [8]